Akoustis Technologies, Inc. (AKTS) Key Metrics

NASDAQ: AKTSValuation, returns, debt and efficiency ratios over 10 years.

AKTS valuation today

Trailing 12 months · as of October 18, 2026
Market cap
$837.6M
Enterprise value
$589.9M
P/E (TTM)
—
Forward P/E
—
PEG ratio
—
Price / sales
83.3
Price / book
2.3
EV / EBITDA
—
Dividend yield
—
Beta
—

AKTS key metrics, 2015–2025

Fiscal year ended December 31, 2025 · U.S. dollars

AKTS returns How much profit the business earns on the capital it uses.

Return on assets−2.0 pts
−21.6%
2025 · hover or tap a bar for each year
2015: −119.4% (−92.3 pts)2017: −80.5% (+38.9 pts)2018: −91.7% (−11.2 pts)2019: −79.9% (+11.8 pts)2020: −68.5% (+11.5 pts)2021: −50.9% (+17.6 pts)2022: −12.0% (+38.9 pts)2023: −22.0% (−10.0 pts)2024: −19.6% (+2.4 pts)2025: −21.6% (−2.0 pts)
20152025
Asset turnover+231.6%
0.02
2025 · hover or tap a bar for each year
2015: 0.062017: 0.00 (−97.3%)2018: 0.05 (+3,300.1%)2019: 0.04 (−26.7%)2020: 0.03 (−19.7%)2021: 0.13 (+339.8%)2022: 0.00 (−100.0%)2023: 0.212024: 0.01 (−96.8%)2025: 0.02 (+231.6%)
20152025

AKTS returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

AKTS debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

AKTS key metrics

2015–2025
Akoustis Technologies, Inc. key metrics by fiscal year
2025202420232022202120202019201820172015
Per share
Revenue per share$0.12$0.04$0.78$0.00$0.28$0.05$0.05$0.06$0.00$0.02
Earnings per share−$1.21−$1.26−$0.82−$0.51−$1.10−$1.21−$1.12−$1.04−$0.54−$0.40
Operating cash flow per share−$1.22$0.42−$0.86−$0.52−$0.84−$0.63−$0.64−$0.68−$0.33−$0.08
Free cash flow per share−$1.40$0.34−$0.97−$0.59−$1.35−$0.93−$0.82−$1.01−$0.43−$0.09
Cash per share$4.32$8.52$2.81$3.69$1.49$1.31$1.10$0.71$0.57$0.31
Book value per share−$2.78−$2.52−$1.33−$0.55$1.91$1.23$0.94$0.66$0.88$0.20
Tangible book value per share−$2.78−$3.07−$2.18−$0.55$1.60$1.22$0.93$0.65$0.87$0.20
Capex per share$0.18$0.08$0.11$0.07$0.51$0.30$0.18$0.34$0.10$0.00
Debt per share$0.22$0.34$0.38$0.05$0.83$0.71$0.66$0.55——
Shares outstanding52.5M34.9M34.9M34.9M54.0M33.7M27.5M20.9M17.0M13.3M
Change in shares outstanding+50.6%0.0%0.0%−35.5%+60.3%+22.5%+31.5%+23.2%+27.3%+5.8%
Returns & profitability
Return on equity (ROE)————−81.7%−121.2%−155.2%−150.6%−103.0%−157.6%
Return on invested capital (ROIC)————−107.6%−144.1%−177.4%−221.7%−403.4%—
Return on assets (ROA)−21.6%−19.6%−22.0%−12.0%−50.9%−68.5%−79.9%−91.7%−80.5%−119.4%
Return on tangible assets−24.1%−14.3%−30.9%−13.0%−41.0%−57.7%−64.9%−74.8%−50.9%−120.9%
Free cash flow margin—800.3%−124.5%—−475.0%————−450.3%
Financial health
Total debt$11.5M$12.0M$13.4M$1.8M$44.9M$23.9M$18.2M$11.5M——
Cash & short-term investments$226.8M$297.2M$97.9M$128.6M$80.5M$44.3M$30.2M$14.8M$9.6M$4.2M
Net debt−$215.2M−$285.2M−$84.5M−$126.8M−$35.6M−$20.4M−$11.9M−$3.4M−$9.6M−$4.2M
Debt / equity————0.430.580.700.83——
Debt / assets0.040.040.110.010.280.330.380.39——
Current ratio7.3715.9816.0725.117.257.549.896.007.427.82
Quick ratio7.3715.8714.8625.116.927.529.875.987.287.74
Interest coverage—-19.6-15.0—-786.4-7.0-9.5-67.6——
Working capital$199.1M$282.0M$94.0M$127.2M$79.1M$40.1M$28.6M$13.2M$8.7M$3.7M
Invested capital−$361.4M−$373.0M−$130.8M−$146.1M$67.8M$21.1M$14.0M$10.5M$5.4M−$1.5M
Tangible asset value−$146.1M−$106.9M−$76.1M−$19.2M$86.4M$41.0M$25.6M$13.6M$14.8M$2.6M
Net current asset value−$180.7M−$113.1M−$68.5M−$25.1M$33.8M$16.3M$9.8M$420,993$6.9M$2.4M
Graham net-net per share−$3.51−$3.20−$1.82−$0.83$0.51$0.44$0.31−$0.02$0.39$0.17
Capital allocation
Capex / revenue147.5%192.5%13.9%—180.6%555.9%341.2%580.8%9,937.4%18.5%
Capex / operating cash flow—19.4%————————
Capex / depreciation4.121.823.365.183.413.121.975.5615.313.76
Stock-based compensation / revenue79.0%152.0%5.4%—66.8%376.2%501.7%454.6%23,025.9%171.0%
R&D / revenue1,038.2%2,754.1%95.6%—232.6%1,146.5%1,333.7%1,098.4%26,089.2%690.1%
SG&A / revenue193.9%760.4%28.3%—134.9%608.4%603.0%728.9%35,482.7%1,151.8%
Efficiency
Days sales outstanding—1,233.264.0—49.364.863.264.9——
Days of inventory on hand—63.591.1—39.617.427.344.0384.6470.2
Days payables outstanding—18.78.7—54.0179.969.2113.4941.5595.8
Cash conversion cycle (days)—1,278.0146.3—34.9-97.721.3-4.5——
Receivables turnover—0.305.71—7.415.635.785.63——
Payables turnover0.0019.5341.79—6.762.035.283.220.390.61
Inventory turnover—5.754.01—9.2120.9913.378.290.950.78
Asset turnover0.020.010.210.000.130.030.040.050.000.06
Average receivables—$5.0M$4.8M—$2.1M$318,000$249,830$214,659——
Average payables$1.8M$1.4M$723,500$2.1M$2.9M$1.2M$192,000$316,758$283,958$46,927
Average inventory—$4.9M$7.5M—$2.1M$115,000$75,778$123,016$116,010$37,032
Intangibles / total assets0.0%5.8%24.4%0.0%10.6%0.8%0.8%0.9%1.1%1.6%

Computed from AKTS's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

AKTS valuation and financial ratios

It ended the year with $11.5 million of debt and $226.8 million in cash and short-term investments, a net cash position of $215.2 million. The share count rose 293.4% from 13.3M to 52.5M over 9 years.

See the AKTS income statement, the AKTS chart for price history, or the AKTS stock overview for the latest quote and news.

AKTS key metrics FAQ

How much debt does Akoustis Technologies have?

Akoustis Technologies had total debt of $11.5 million at the end of fiscal 2025 and more cash than debt.

What is Akoustis Technologies's current ratio?

Akoustis Technologies's current ratio was 7.37 at the end of fiscal 2025: current assets were 7.37 times current liabilities.

Biotechnology key metrics